Non-coding 2024
Top Research Directions
The 3 research directions with Non-coding 2024 papers, ranked by paper count. Share is the fraction of the edition’s papers in the direction.
| # | Direction | Papers | Share |
|---|---|---|---|
| 1 | Mechanisms of Cap-Independent Translation Initiation | 1 | 50.0% |
| 2 | Molecular Scaffolding by Nuclear Long Non-Coding RNAs | 1 | 50.0% |
| 3 | Uncovering the Biochemical Mechanisms of Long Noncoding RNAs | 1 | 50.0% |
Download all directions as CSV
Institutions
Institutions credited by Non-coding 2024 papers: a paper credits every institution named in its affiliations, once. 6 institutions share 1 credited papers.
| # | Institution | Papers | Share |
|---|---|---|---|
| 1 | 02axars19 | 1 | 100.0% |
| 2 | Chinese Academy of Sciences | 1 | 100.0% |
| 3 | Institute of Modern Physics | 1 | 100.0% |
| 4 | Lanzhou University | 1 | 100.0% |
| 5 | Northwest Normal University | 1 | 100.0% |
| 6 | University of Chinese Academy of Sciences | 1 | 100.0% |
Download all institutions as CSV
About this data
Papers. Non-coding 2024 lists 2 papers on Lacuna, duplicate versions counted once; rejected and withdrawn submissions are left out.
Directions. Directions are Lacuna’s clustering of the concept elements extracted from each paper, so a paper can belong to several and direction counts add up to more than the paper count. A direction’s share is its papers divided by the edition’s papers.
Institutions. A paper credits each institution named in its affiliations, resolved to a ROR record, once. 1 of 2 papers (50.0%) credit at least one institution and are the base for institution shares; the rest have no resolved affiliation yet.
Data. Counts come from Lacuna’s data build of 2026-11-19 and change as papers are added. Tables as CSV: directions · institutions. Cite as: Lacuna, “Non-coding 2024”, https://lacuna.tiptreesystems.com/venue/non-coding/2024.
Papers
| Title |
|---|
| New mechanism of LncRNA: In addition to act as a ceRNA |
| Targeting LINC00665/miR-199b-5p/SERPINE1 axis to inhibit trastuzumab resistance and tumorigenesis of gastric cancer via PI3K/AKt pathway |